These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16311689)

  • 1. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia].
    Santolaya ME; Rabagliati R; Bidart T; Payá E; Guzmán AM; Morales R; Braun S; Bronfman L; Ferrés M; Flores C; García P; Letelier LM; Puga B; Salgado C; Thompson L; Tordecilla J; Zubieta M; ;
    Rev Chilena Infectol; 2005; 22 Suppl 2():S79-113. PubMed ID: 16311689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in the epidemiology of infections in patients with febrile neutropenia].
    Karthaus M; Carratala J
    Wien Med Wochenschr; 2001; 151(3-4):47-52. PubMed ID: 11789419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
    Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
    J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Febrile neutropenia in the child with cancer. Current concepts about risk assessment and selective management].
    Santolaya ME
    Rev Med Chil; 2001 Dec; 129(12):1449-54. PubMed ID: 12080883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic procedures and management of Fever in pediatric cancer patients].
    Laws HJ; Ammann RA; Lehrnbecher T
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S9-16. PubMed ID: 16288350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients.
    Schlapbach LJ; Aebi C; Otth M; Luethy AR; Leibundgut K; Hirt A; Ammann RA
    Pediatr Blood Cancer; 2007 Jul; 49(1):11-6. PubMed ID: 17143875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients.
    Schlapbach LJ; Aebi C; Otth M; Leibundgut K; Hirt A; Ammann RA
    Pediatr Infect Dis J; 2007 Nov; 26(11):989-94. PubMed ID: 17984804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer.
    Quezada G; Sunderland T; Chan KW; Rolston K; Mullen CA
    Pediatr Blood Cancer; 2007 Mar; 48(3):273-7. PubMed ID: 16435377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supportive care in children.
    Santolaya ME
    Curr Opin Oncol; 2010 Jul; 22(4):323-9. PubMed ID: 20520543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in fever and neutropenia in children with cancer: What did we learn?
    te Poele EM; Tissing WJ; Kamps WA; de Bont ES
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):45-55. PubMed ID: 19195908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
    Ritchie S; Palmer S; Ellis-Pegler R
    Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk prediction of fever in neutropenia in children with cancer: a step towards individually tailored supportive therapy?
    Wicki S; Keisker A; Aebi C; Leibundgut K; Hirt A; Ammann RA
    Pediatr Blood Cancer; 2008 Dec; 51(6):778-83. PubMed ID: 18726920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of febrile neutropenia in patients with solid tumors].
    Novotný J; Petruzelka L; Jedlicková A; Mikolásová B
    Cas Lek Cesk; 1998 Nov; 137(22):694-9. PubMed ID: 9929937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Invasive fungal infections in children with cancer, neutropenia and fever, in Chile].
    Lucero Y; Brücher R; Alvarez AM; Becker A; Cofré J; Enríquez N; Payá E; Salgado C; Santolaya ME; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M; O'Ryan M
    Rev Med Chil; 2002 Oct; 130(10):1139-46. PubMed ID: 12491831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient management of febrile neutropenia: time to revise the present treatment strategy.
    Carstensen M; Sørensen JB
    J Support Oncol; 2008; 6(5):199-208. PubMed ID: 18551855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW; Treish IM; Zaru L
    J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.